Ampersand Capital Partners Mergers and Acquisitions Summary

Private Equity Profile

In the last 3 years, Ampersand Capital Partners has acquired 7 companies. It has also invested in 10 others.

Ampersand Capital Partners’ most common sectors for investment are life science (49%) and medical products (25%). The Firm’s most common investment types include buyout (lbo, mbo, mbi) (33%) and growth capital (30%). In total, Ampersand Capital Partners has invested in 20 US states and 5 different countries. Its largest (disclosed) acquisition occurred in 2013 when it acquired BioClinica for $123M.

In the last 3 years, Ampersand Capital Partners has exited 9 companies. The Firm’s most common exit type is trade sale (72%). Ampersand Capital Partners’ largest (disclosed) exit occurred in 2008 when it sold Talecris Biotherapeutics Holdings Corp for $3.1B.

Join Mergr to view Ampersand Capital Partners’ full profile and discover more large private equity firms just like it.

M&A Summary

  • M&A Total Activity100
    • M&A Buy Activity58
    • M&A Sell Activity42
  • Total Sectors Invested 12
  • Total Countries Invested 5
  • M&A Buy/Sell Connections 53
  • M&A Advisors 1

Ampersand Capital Partners

55 William St., Ste. 240,
Wellesley, Massachusetts 02481
United States
(781) 239-0700
www.ampersandcapital.com
info@ampersandcapital.com

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products, Test/Measurement Equipment

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital, Recapitalization, Secondary Buyout, Stake Purchase, Venture

Geographic Preferences: East US, Midwest US, South US, West US, Canada, United Kingdom, Western Europe, Eastern Europe, Scandinavia

Transaction Criteria Min Max
Target Revenue 10 100
Target EBITDA - -
Investment Size 10 100
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '16 '17 '18 '19 '20 '21 T
Buy (4.0/yr) # 38 3 6 6 4 1 58
vol $161M $161M
Sell (2.2/yr) # 31 2 6 1 1 1 42
vol $3.7B $828M $1.7B $6.2B
  100

Most Recent M&A

Company Date Value Type
Bioventus LLC 2021-02-04 - IPO
Durham, North Carolina · www.bioventusglobal.com
Genezen Laboratories, Inc. 2021-01-05 - Growth Capital
Indianapolis, Indiana · www.genezenlabs.com
American Laboratory Products Co. (ALPCO) 2020-09-21 - Recapitalization
Salem, New Hampshire · www.alpco.com
GeneWerk GmbH 2020-09-21 - Growth Capital
Heidelberg, Germany · www.genewerk.com
Canopy Biosciences LLC 2020-09-11 - Add-on Acquisition
St. Louis, Missouri · www.canopybiosciences.com
Tjoapack Netherlands B.V. 2020-04-21 - Buyout (LBO, MBO, MBI)
Etten-Leur, Netherlands · www.tjoapack.com
Interpace Biosciences, Inc. 2020-01-13 - Stake Purchase
Parsippany, New Jersey · www.interpace.com
Canopy Biosciences LLC 2019-12-04 - Growth Capital
St. Louis, Missouri · www.canopybiosciences.com
Arranta Bio 2019-10-29 - Venture
Watertown, Massachusetts · www.arrantabio.com
vivitide 2019-10-08 - Secondary Buyout
Gardner, Massachusetts · www.vivitide.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Nexelis 2018-09-04 GlaxoSmithKline plc - The Clinical Laboratory Science 2021-01-20 5
Laval, Quebec · www.nexelis.com Marburg, Germany
Alcami Corp. 2018-06-01 Alcami Corp. - API Facility 2020-10-01 1
Durham, North Carolina · www.alcaminow.com Germantown, Wisconsin

M&A by Sector

Sector Current # Value All-time # Value
Life Science 12 (67%) - 28 (48%) 123M (76%)
Medical Products 3 (17%) 20M (100%) 14 (24%) 38M (24%)
Healthcare Services - - 3 (5%) -
Software 1 (6%) - 3 (5%) -
Chemicals - - 2 (3%) -
Consumer Products - - 2 (3%) -
Consumer Services - - 1 (2%) -
Information Technology - - 1 (2%) -
Manufacturing 1 (6%) - 1 (2%) -
Packaging 1 (6%) - 1 (2%) -
Semiconductors - - 1 (2%) -
Test/Measurement Equipment - - 1 (2%) -
Total 18 $20M 58 $161M

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 12 (67%) 20M (100%) 52 (90%) 161M (100%)
  Massachusetts 5 (28%) - 12 (21%) -
  California 1 (6%) - 9 (16%) -
  New Jersey 1 (6%) - 6 (10%) 123M (76%)
  Arizona 1 (6%) 20M (100%) 3 (5%) 20M (12%)
  North Carolina 1 (6%) - 3 (5%) -
  Missouri - - 3 (5%) 18M (11%)
  Indiana 1 (6%) - 2 (3%) -
  Minnesota - - 2 (3%) -
  Virginia 1 (6%) - 1 (2%) -
  New Hampshire 1 (6%) - 1 (2%) -
  Wisconsin - - 1 (2%) -
  Washington - - 1 (2%) -
  Rhode Island - - 1 (2%) -
  Ohio - - 1 (2%) -
  Michigan - - 1 (2%) -
  Maryland - - 1 (2%) -
  Louisiana - - 1 (2%) -
  Georgia - - 1 (2%) -
  Florida - - 1 (2%) -
  Colorado - - 1 (2%) -
Germany 2 (11%) - 2 (3%) -
Netherlands 2 (11%) - 2 (3%) -
United Kingdom 1 (6%) - 1 (2%) -
Canada 1 (6%) - 1 (2%) -
  Quebec 1 (6%) - 1 (2%) -
Domestic 12 (67%) 20M (100%) 52 (90%) 161M (100%)
Cross-border 6 (33%) - 6 (10%) -
Total 18 $20M 58 $161M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Buyout (LBO, MBO, MBI) 3 (17%) - 19 (33%) -
Growth Capital 9 (50%) 20M (100%) 17 (29%) 20M (12%)
Venture 1 (6%) - 10 (17%) 18M (11%)
Divestiture 1 (6%) - 4 (7%) -
Recapitalization 1 (6%) - 3 (5%) -
Secondary Buyout 2 (11%) - 2 (3%) -
Going Private - - 1 (2%) 123M (76%)
Special Situations/Distressed - - 1 (2%) -
Stake Purchase 1 (6%) - 1 (2%) -
Total 18 $20M 58 $161M

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 17 (40%) 6.1B (98%)
Trade Sale 14 (33%) 127M (2%)
IPO 3 (7%) -
Merger 3 (7%) -
Secondary Sale 3 (7%) -
Recapitalization 1 (2%) -
Unknown 1 (2%) -
Total 42 $6.2B

Top M&A Advisors

Legal Deals
Edwards Wildman Palmer LLP
1

Deal Values

buy # Total
$100M to $1B 1 $123M
< $100M 2 $38M
TOTAL $161M
Largest BioClinica, Inc.
$123M (2013-03-13)
sell # Total
> $1B 2 $4.8B
$100M to $1B 6 $1.3B
< $100M 2 $76M
TOTAL $6.2B
Largest Talecris Biotherapeutics Holdings Corp
$3.1B (2008-08-12)

M&A Connections

Deals
Acquired from
Investor(s)
3%
2 (3%)
Strategic(s)
7%
4 (7%)
Exited to
Investor(s)
10%
4 (10%)
Strategic(s)
76%
32 (76%)

 Subscribe to unlock this and 161,366
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.1K Private Equity Firms
  • 150K M&A Transactions
  • 157K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.2K M&A Advisors
    (Investment Banks and Law Firms)
  • 48K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.